Cargando…
Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong – Clinical outcomes, barriers to vaccination, and urgency for reform()
INTRODUCTION: Hong Kong has had a low incidence of COVID-19 vaccine related anaphylaxis, partly due to its Vaccine Allergy Safety (VAS) guidelines for screening those at higher risk of COVID-19 vaccine-associated allergic reactions. We characterize the initial experience of the VAS clinics, as well...
Autores principales: | Chiang, Valerie, Mok, Sabrina Wing Shan, Chan, June King Chi, Leung, Wai Yan, Ho, Carmen Tze Kwan, Au, Elaine Y.L., Lau, Chak Sing, Lee, Tak Hong, Li, Philip Hei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685183/ https://www.ncbi.nlm.nih.gov/pubmed/34956434 http://dx.doi.org/10.1016/j.waojou.2021.100622 |
Ejemplares similares
-
Updated consensus statements on COVID-19 Vaccine Allergy Safety in Hong Kong
por: Chiang, Valerie, et al.
Publicado: (2022) -
Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong
por: Chiang, Valerie, et al.
Publicado: (2021) -
Prevalence, Incidence, and Sensitization Profile of β-lactam Antibiotic Allergy in Hong Kong
por: Li, Philip H., et al.
Publicado: (2020) -
Chronic Spontaneous Urticaria in Hong Kong: Clinical Characteristics, Real-World Practice and Implications for COVID-19 Vaccination
por: Kan, Andy Ka Chun, et al.
Publicado: (2022) -
Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy
por: Wong, Jane CY, et al.
Publicado: (2020)